An overview of SARS-COV-2 related hepatic injury

Balaban, Hatice

doi:10.14744/hf.2021.2021.0020

Cited by 4 publications

(1 citation statement)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous observations revealed that enzymatic features of liver disorder accompanying COVID-19 might predict a more severe course of the disease, poorer overall outcome and a higher rate of mortality [151][152][153][154][155]. In general, individuals affected with SARS-CoV-2 infection usually present a hepatocellular pattern of liver injury (with a threefold increase in aminotransferases above the upper limit of normal (ULN)) or a mixed one (hepatocellular pattern together with a twofold increase in ALP/GGT) [156]. Fulfilling the above-mentioned criteria indicated a significant risk of more severe presentation due to COVID-19.…”

Section: Covid-19 In Patients Without Previously Diagnosed Liver Diso...mentioning

confidence: 99%

COVID-19, Possible Hepatic Pathways and Alcohol Abuse—What Do We Know up to 2023?

Michalak,

Lach,

Szczygieł

et al. 2024

IJMS

View full text Add to dashboard Cite

The pandemic period due to coronavirus disease 2019 (COVID-19) revolutionized all possible areas of global health. Significant consequences were also related to diverse extrapulmonary manifestations of this pathology. The liver was found to be a relatively common organ, beyond the respiratory tract, affected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Multiple studies revealed the essential role of chronic liver disease (CLD) in the general outcome of coronavirus infection. Present concerns in this field are related to the direct hepatic consequences caused by COVID-19 and pre-existing liver disorders as risk factors for the severe course of the infection. Which mechanism has a key role in this phenomenon—previously existing hepatic disorder or acute liver failure due to SARS-CoV-2—is still not fully clarified. Alcoholic liver disease (ALD) constitutes another not fully elucidated context of coronavirus infection. Should the toxic effects of ethanol or already developed liver cirrhosis and its consequences be perceived as a causative or triggering factor of hepatic impairment in COVID-19 patients? In the face of these discrepancies, we decided to summarize the role of the liver in the whole picture of coronavirus infection, paying special attention to ALD and focusing on the pathological pathways related to COVID-19, ethanol toxicity and liver cirrhosis.

show abstract

Section: Covid-19 In Patients Without Previously Diagnosed Liver Diso...mentioning

confidence: 99%

COVID-19, Possible Hepatic Pathways and Alcohol Abuse—What Do We Know up to 2023?

Michalak,

Lach,

Szczygieł

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates

et al. 2022

View full text Add to dashboard Cite

The COVID-19 pandemic has exemplified that rigorous evaluation in large animal models is key for translation from promising in vitro results to successful clinical implementation. Among the drugs that have been largely tested in clinical trials but failed so far to bring clear evidence of clinical efficacy is favipiravir, a nucleoside analogue with large spectrum activity against several RNA viruses in vitro and in small animal models. Here, we evaluate the antiviral activity of favipiravir against Zika or SARS-CoV-2 virus in cynomolgus macaques. In both models, high doses of favipiravir are initiated before infection and viral kinetics are evaluated during 7 to 15 days after infection. Favipiravir leads to a statistically significant reduction in plasma Zika viral load compared to untreated animals. However, favipiravir has no effects on SARS-CoV-2 viral kinetics, and 4 treated animals have to be euthanized due to rapid clinical deterioration, suggesting a potential role of favipiravir in disease worsening in SARS-CoV-2 infected animals. To summarize, favipiravir has an antiviral activity against Zika virus but not against SARS-CoV-2 infection in the cynomolgus macaque model. Our results support the clinical evaluation of favipiravir against Zika virus but they advocate against its use against SARS-CoV-2 infection.

show abstract

Prevention, diagnostic evaluation, management and prognostic implications of liver disease in critically ill patients with COVID-19

Valsamaki¹,

Xanthoudaki²,

Oikonomou³

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, broke out in December 2019 in Wuhan city of China and spread rapidly worldwide. Therefore, by March 2020, the World Health Organization declared the disease a global pandemic. Apart from the respiratory system, various other organs of the human body are also seriously affected by the virus. Liver injury in patients with a severe form of COVID-19 is estimated to be 14.8%-53.0%. Elevated levels of total bilirubin, aspartate aminotransferase and alanine aminotransferase and low levels of serum albumin and prealbumin are the main laboratory findings. Patients with pre-existing chronic liver disease and cirrhosis are much more prone to develop severe liver injury. This literature review presented the recent scientific findings regarding the pathophysiological mechanisms responsible for liver injury in critically ill patients with COVID-19, the various interactions between drugs used to treat the disease and the function of the liver and the specific tests providing the possibility of early diagnosis of severe liver injury in these patients. Moreover, it highlighted the burden that COVID-19 put on health systems worldwide and its effect on transplant programs and the care provided to critically ill patients in general and particularly to those with chronic liver disease.

show abstract

An overview of SARS-COV-2 related hepatic injury

Cited by 4 publications

References 86 publications

COVID-19, Possible Hepatic Pathways and Alcohol Abuse—What Do We Know up to 2023?

COVID-19, Possible Hepatic Pathways and Alcohol Abuse—What Do We Know up to 2023?

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates

Prevention, diagnostic evaluation, management and prognostic implications of liver disease in critically ill patients with COVID-19

Contact Info

Product

Resources

About